• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » John Potthoff joins SynteractHCR board of directors

John Potthoff joins SynteractHCR board of directors

October 26, 2017
CenterWatch Staff

SynteractHCR, a full-service CRO, announced the appointment of industry veteran John Potthoff to its Board of Directors, effective immediately. Potthoff draws on extensive operational, business development and leadership experience derived through his 25-year career dedicated to clinical development.

Potthoff is a founder and CEO of Elligo Health Research, a leading clinical research infrastructure provider whose mission is to redefine the clinical trial process. Prior to this, he served as CEO of Theorem Clinical Research and COO of INC Research, having successfully contributed to the impressive growth of both CROs. In 2000 he founded and was CEO of Tanistry, a CNS focused CRO, which was acquired by INC Research. He currently sits on the Board of Directors for Chesapeake IRB and previously served as a member of the Board of Directors for Chiltern.

“I have had the pleasure of working directly with John in the past. He is both a respected business leader and an experienced board member in our industry,” said Steve Powell, CEO of SynteractHCR. “Drawing on his years of experience as a CRO executive, industry leader and now CEO of a company that implements new approaches to clinical trial conduct, John will provide fresh insights and counsel invaluable to SynteractHCR and our customers. I am delighted John has agreed to join our Board.”

"We have known John for over 10 years and have seen how he has played a leadership role in building value at INC Research and Theorem," added Ramsey Frank, partner and co-founder of Amulet Capital. "We welcome John’s addition to the board and are confident his industry acumen will help us build on SynteractHCR’s leading market position and continue to advance the company’s success.”

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing